TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03456388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine Hydrochloride Enteric-coated Tablets
Description: There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo enteric-coated tablets
Description: There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
Study: NCT03510325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone long-acting injection
Description: long-acting injection
Study: NCT01020279

Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib, Ketoprofen
Description: Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d.

Intervention type: DRUG
Group type: OTHER
Intervention: Ketoprofen
Description: Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
Study: NCT04093336

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human umbilical cord mesenchymal stem cells
Description: The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized treatment
Description: standardized treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standardized treatment
Description: standardized treatment
Study: NCT01995955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a new non-invasive imaging technique
Description: a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
Study: NCT03022981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: SOF/VEL FDC 200/50 mg oral granules
Study: NCT02248740

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the incompetent small saphenous vein
Description: For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the incompetent small saphenous vein
Description: For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
Study: NCT00259688

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CPAP therapy for subjects diagnosed with sleep apnea
Description: CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
Study: NCT03527953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tetric EvoCeram Bulkfill
Description: The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surefil SDR Flowable bulkfill
Description: The preparation will be etched. A two-step etch-and-rinse adhesive, Prime\&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
Study: NCT01611220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RePAN
Description: The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
Study: NCT02043119

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding Clinic
Study: NCT01340508

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
Study: NCT05451680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure device
Description: Negative-pressure therapy postoperatively on the full-thickness skin graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Conventional dressing postoperatively on the full-thickness skin graft
Study: NCT04266496

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Frequency Volume Chart
Description: Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.
Study: NCT03674918

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 h ambulatory blood pressure measurements
Description: 24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
Study: NCT03102073

Intervention type: DIAGNOSTIC_TEST
Intervention: Radner test
Description: * The A5 reading booklet is held by the subject~* The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~* The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~* One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~* Stop criterion: reading time longer than 20 seconds or severe errors.
Study: NCT04266496

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Frequency Volume Chart
Description: Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Collect urine during 1 day
Description: Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Blood collection to measure plasma sodium and osmolality.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Measurement of the circumference of the lower legs
Description: Circumference of the lower legs wil be measured twice:~* After awakening, when still laying dowing in bed~* Before goin to sleep~Circumference should be measured 2 cm above the medial malleolus
Study: NCT02990195

Intervention type: OTHER
Group type: OTHER
Intervention: Chyme reinfusion
Study: NCT00724113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infiltration intra articular
Description: infiltration intra articular at inclusion with XYLOCAINE 1%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARTHRO distension plus intensive mobilisation
Description: ARTHRO distension plus intensive mobilisation
Study: NCT03140982

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FOUR coma scale and frontal espectrograpy evaluation
Description: systematic evaluation using the validated FOUR coma scale during propofol administration

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FOUR coma scale and frontal espectrograpy evaluation
Description: systematic evaluation using the validated FOUR coma scale during propofol administration
Study: NCT02096263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: 3 doses administered intramuscularly in the right thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix
Description: 3 doses administered intramuscularly in the right thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB
Description: 4 doses administered intramuscularly in the upper left thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel
Description: 4 doses administered intramuscularly in the right thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: 2 or 3 doses administered intramuscularly in the upper left thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix
Description: 1 dose administered intramuscularly in the right thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix
Description: 1 dose administered intramuscularly in the right thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: 1 dose administered intramuscularly in the left thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar13
Description: 3 doses administered intramuscularly in the lower left thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: 3 doses administered intramuscularly in the lower left thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: 3 doses administered intramuscularly in the lower left thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 2 doses administered orally
Study: NCT03527953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: everX fiber-reinforced resin
Description: The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
Study: NCT01772485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
Study: NCT01019668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin PDT, half-dose
Description: half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin PDT, half-dose
Description: half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verteporfin PDT, half-fluence
Description: half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Study: NCT02096263

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: 2 doses administered orally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: 2 doses administered orally
Study: NCT01875718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UC1010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UC1010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04534348

Intervention type: DEVICE
Intervention: 70% isopropyl alcohol-impregnated catheter caps
Description: Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
Study: NCT00850941

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Information collection.
Study: NCT02003937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic conditioning
Description: Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
Study: NCT03653039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tritube
Description: The ultra thin tribute is used used for the ventilation of the patients in this arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard enditracheal tube
Description: A standard endotracheal tube is used used for the ventilation of the patients in this arm
Study: NCT02160639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diabetes self management support
Description: diabetes self management support is telephonic and provided by health investigators
Study: NCT03560804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
Study: NCT03441503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Child HCAHPS: Automated day-of-discharge survey
Description: Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
Study: NCT03560804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
Study: NCT03097549

Intervention type: DEVICE
Group type: OTHER
Intervention: Tät®II Information app
Description: Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
Study: NCT01019668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verteporfin PDT, half-fluence
Description: half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Study: NCT04226521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracoropreal photopheresis
Description: Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
Study: NCT03097549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tät®II Treatment app
Description: Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
Study: NCT02183272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Ketamine
Description: Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Saline Placebo
Description: Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
Study: NCT04373967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza®.
Description: Patients will receive Victoza®. Both products will be provided as pen-injector.
Study: NCT02424292

Intervention type: OTHER
Intervention: Physical activity
Description: Physical activity in a personalised program.
Study: NCT03266913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotics drop
Study: NCT04533074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-visit regeneration protocol
Description: In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-visits regeneration protocol
Description: In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
Study: NCT01362452

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion
Description: Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion
Description: Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Infusion
Description: Cord blood infusion on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Infusion
Description: Cord blood infusion on Day 0.
Study: NCT01397604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLA-AF
Description: GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLA-SE
Description: GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Squalene
Description: Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
Study: NCT01073124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline Load Test
Description: Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline Load Test
Description: Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
Study: NCT04596865

Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Date of surgery 01/06/2010 - 31/05/2015

Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Date of surgery 01/06/2010 - 31/05/2015

Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Date of surgery 01/06/2010 - 31/05/2015
Study: NCT04464525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Description: Film-coated tablet administered orally.